Abstract
Ovarian cancer, the worldwide leading cause of gynecological cancer-related death, is primarily treated by surgery followed by platinum chemotherapy. Though the tumor initially responds to the treatment, only 30% of 5 year survival period has been recorded and this is mainly attributed to the acquired chemo resistance and frequent recurrence of tumor. Combination chemotherapy as well, led to therapeutic failure due to non-specificity and subsequent side effects. However, polymer mediated drug delivery aids in overcoming these impediments. In particular, three dimensional macromolecule “Dendrimer” with its unique properties and numerous functionalities offer various advantages over the conventional approach and may improve the treatment outcome in patients with ovarian cancer. The present review highlights the various strategies employed using dendrimers to achieve targeted drug delivery and enhanced therapeutic efficacy in ovarian cancer.
Keywords: Ovarian cancer, asymptomatic, drug delivery systems, dendrimer, strategies, targeted drug delivery.
Current Pharmaceutical Design
Title:Effective Strategies and Applications of Dendrimers in the Treatment of Ovarian Cancer
Volume: 23 Issue: 21
Author(s): Akila Kesavan, Suresh Babu Pakala, Suresh K. Rayala*Ganesh Venkatraman*
Affiliation:
- Department of Biotechnology, IIT-M, Chennai-36,India
- Department of Human Genetics, Faculty of Biomedical Sciences, Technology & Research, & Sri Ramachandra Center for Biomedical Nanotechnology, Sri Ramachandra University, Porur, Chennai-600116, Tamil Nadu,India
Keywords: Ovarian cancer, asymptomatic, drug delivery systems, dendrimer, strategies, targeted drug delivery.
Abstract: Ovarian cancer, the worldwide leading cause of gynecological cancer-related death, is primarily treated by surgery followed by platinum chemotherapy. Though the tumor initially responds to the treatment, only 30% of 5 year survival period has been recorded and this is mainly attributed to the acquired chemo resistance and frequent recurrence of tumor. Combination chemotherapy as well, led to therapeutic failure due to non-specificity and subsequent side effects. However, polymer mediated drug delivery aids in overcoming these impediments. In particular, three dimensional macromolecule “Dendrimer” with its unique properties and numerous functionalities offer various advantages over the conventional approach and may improve the treatment outcome in patients with ovarian cancer. The present review highlights the various strategies employed using dendrimers to achieve targeted drug delivery and enhanced therapeutic efficacy in ovarian cancer.
Export Options
About this article
Cite this article as:
Kesavan Akila, Pakala Babu Suresh, Rayala K. Suresh*, Venkatraman Ganesh*, Effective Strategies and Applications of Dendrimers in the Treatment of Ovarian Cancer, Current Pharmaceutical Design 2017; 23 (21) . https://dx.doi.org/10.2174/1381612823666170223165541
DOI https://dx.doi.org/10.2174/1381612823666170223165541 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Small Molecule Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Non Small Cell Lung Cancer Treatment
Current Cancer Therapy Reviews Designing Prodrugs Based on Special Residues of Human Serum Albumin
Current Topics in Medicinal Chemistry T Cell Redirecting Therapies for Cancer Treatment
Current Cancer Drug Targets Clostridium Difficile Infection Following Chemotherapy
Recent Patents on Anti-Infective Drug Discovery Gonadotropin-Releasing Hormone (GnRH) Receptors in Tumors: a New Rationale for the Therapeutical Application of GnRH Analogs in Cancer Patients?
Current Cancer Drug Targets Macrophages in Immunopathology of Atherosclerosis: A Target for Diagnostics and Therapy
Current Pharmaceutical Design Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery Cancer Chemoprevention with Green Tea Catechins: From Bench to Bed
Current Drug Targets Development of Novel Therapeutics Targeting the Urokinase Plasminogen Activator Receptor (uPAR) and Their Translation Toward the Clinic
Current Pharmaceutical Design MicroRNAs and Cancer Therapy – From Bystanders to Major Players
Current Medicinal Chemistry Can we Target the Chemokine Network for Cancer Therapeutics?
Current Cancer Drug Targets Azacitidine, as a DNMT Inhibitor Decreases hTERT Gene Expression and Telomerase Activity More Effective Compared with HDAC Inhibitor in Human Head and Neck Squamous Cell Carcinoma Cell Lines
Current Molecular Pharmacology Selectively Replicating Adenoviruses for Oncolytic Therapy
Current Cancer Drug Targets Moving Beyond VEGF for Anti-angiogenesis Strategies in Gynecologic Cancer
Current Pharmaceutical Design Blockade of Neoangiogenesis, a New and Promising Technique to Control the Growth of Malignant Tumors and their Metastases
Current Vascular Pharmacology Expression of CDK8 and CDK8-interacting Genes as Potential Biomarkers in Breast Cancer
Current Cancer Drug Targets Xeno-Cannibalism as an Exacerbation of Self-Cannibalism: A Possible Fruitful Survival Strategy for Cancer Cells
Current Pharmaceutical Design Cdc20: A Potential Novel Therapeutic Target for Cancer Treatment
Current Pharmaceutical Design E-Cadherin Upregulation as a Therapeutic Goal in Cancer Treatment
Mini-Reviews in Medicinal Chemistry Nitric Oxide-Releasing Biomaterials for Biomedical Applications
Current Medicinal Chemistry